Alsa Ventures

General contacts
Investor type

VC

Founded

2019

AUM

-

Location

London, England, United Kingdom

Investment Ticket

$10-50 m

Investment Stage

Pre-seed Seed Series A Series B Late Stage (Series C+)

Region of investment

Europe
Investor profile last updated: 29 August, 2026

Profile

ALSA Ventures is an international life science investor based in London, focused on novel therapeutics. The investment team has a strong background in the pharmaceutical, biotechnology, and CRO industries, bringing extensive practical experience to their portfolio companies. They differentiate themselves by believing in the potential of life sciences innovation to create valuable businesses with a global impact.

The firm primarily invests in biotechnology companies that are developing novel drugs and modalities across a wide range of disease areas. They are involved in various stages of drug development, from company formation to participating in syndicates with co-investors. Their investment strategy reflects a commitment to supporting breakthroughs in therapeutics.

Notable investments include companies such as Eclipse - novel therapies, and others focused on innovative drug development. ALSA Ventures aims to foster advancements that can significantly benefit patients and the healthcare landscape.

Industry

Biotechnology Healthcare Services Medical Devices Pharmaceuticals MedTech Life Sciences HealthTech

Contacts

Name
Title
Email
Social Networks
avatar
Graeme R. Martin Ph.D. Chief Investment Officer
Chief Investment Officer
g•••@•••
LinkedIn
avatar
Alek Safarian CEO
CEO
a•••@•••
LinkedIn
Upgrade to see contacts
avatar
Sb20CZdn7kWtQUED Sb20CZdn7kWtQUED
Sb20CZdn7kWtQUED
[email protected]
linkedin twitter
avatar
Sb20CZdn7kWtQUED Sb20CZdn7kWtQUED
Sb20CZdn7kWtQUED
[email protected]
linkedin twitter
avatar
Sb20CZdn7kWtQUED Sb20CZdn7kWtQUED
Sb20CZdn7kWtQUED
[email protected]
linkedin twitter
Investment-team contacts for Alsa Ventures — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about Alsa Ventures

Alsa Ventures is a venture capital firm. It backs companies at Pre-seed, Seed, Series A, Series B and Late Stage (Series C+), writing tickets of $10-50 m.
Alsa Ventures is located in London, England, United Kingdom.
Alsa Ventures was founded in 2019.
Alsa Ventures invests in companies and startups in Biotechnology, Healthcare Services, Medical Devices, Pharmaceuticals, MedTech, Life Sciences, HealthTech.
Alsa Ventures invests in companies and startups in Europe.
Alsa Ventures invests in companies and startups at Pre-seed, Seed, Series A, Series B, Late Stage (Series C+).
Alsa Ventures usually invests $10-50 m on average.
Alsa Ventures can be reached through its website alsaventures.com, its LinkedIn page and its X account. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for Alsa Ventures — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query Alsa Ventures directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 29 August, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.